BMO Capital Markets Boosts Intercept Pharmaceuticals (ICPT) Price Target to $155.00

Intercept Pharmaceuticals (NASDAQ:ICPT) had its price target raised by BMO Capital Markets from $152.00 to $155.00 in a report published on Thursday morning. BMO Capital Markets currently has an outperform rating on the biopharmaceutical company’s stock.

Other research analysts have also issued reports about the company. Wedbush reissued a buy rating and set a $253.00 price target on shares of Intercept Pharmaceuticals in a report on Friday, December 22nd. Cowen reissued a buy rating and set a $112.00 price target on shares of Intercept Pharmaceuticals in a report on Wednesday, November 1st. Needham & Company LLC reissued a hold rating on shares of Intercept Pharmaceuticals in a report on Wednesday, November 1st. Oppenheimer reissued a hold rating on shares of Intercept Pharmaceuticals in a report on Tuesday, October 24th. Finally, Citigroup set a $74.00 price target on Intercept Pharmaceuticals and gave the company a hold rating in a report on Thursday, December 21st. Four analysts have rated the stock with a sell rating, ten have given a hold rating and ten have issued a buy rating to the company. Intercept Pharmaceuticals presently has a consensus rating of Hold and an average target price of $128.75.

Intercept Pharmaceuticals (NASDAQ ICPT) opened at $61.16 on Thursday. The company has a market capitalization of $1,535.24, a price-to-earnings ratio of -4.25 and a beta of -2.13. The company has a current ratio of 5.95, a quick ratio of 5.95 and a debt-to-equity ratio of 3.15. Intercept Pharmaceuticals has a fifty-two week low of $51.05 and a fifty-two week high of $135.59.

Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its quarterly earnings results on Wednesday, February 14th. The biopharmaceutical company reported ($4.43) EPS for the quarter, missing analysts’ consensus estimates of ($3.39) by ($1.04). The business had revenue of $37.69 million for the quarter, compared to analyst estimates of $39.01 million. Intercept Pharmaceuticals had a negative net margin of 275.18% and a negative return on equity of 207.27%. Intercept Pharmaceuticals’s revenue for the quarter was up 173.1% on a year-over-year basis. During the same period last year, the business posted ($4.84) earnings per share. sell-side analysts predict that Intercept Pharmaceuticals will post -13.16 EPS for the current fiscal year.

A number of hedge funds have recently made changes to their positions in the stock. WFG Advisors LP boosted its stake in Intercept Pharmaceuticals by 16.4% during the second quarter. WFG Advisors LP now owns 888 shares of the biopharmaceutical company’s stock valued at $108,000 after buying an additional 125 shares in the last quarter. Voya Investment Management LLC boosted its position in shares of Intercept Pharmaceuticals by 4.7% in the 2nd quarter. Voya Investment Management LLC now owns 6,994 shares of the biopharmaceutical company’s stock valued at $847,000 after purchasing an additional 313 shares during the period. PNC Financial Services Group Inc. boosted its position in shares of Intercept Pharmaceuticals by 23.3% in the 2nd quarter. PNC Financial Services Group Inc. now owns 2,490 shares of the biopharmaceutical company’s stock valued at $302,000 after purchasing an additional 470 shares during the period. Alliancebernstein L.P. boosted its position in shares of Intercept Pharmaceuticals by 6.2% in the 2nd quarter. Alliancebernstein L.P. now owns 9,459 shares of the biopharmaceutical company’s stock valued at $1,145,000 after purchasing an additional 550 shares during the period. Finally, California Public Employees Retirement System boosted its position in shares of Intercept Pharmaceuticals by 2.3% in the 2nd quarter. California Public Employees Retirement System now owns 31,000 shares of the biopharmaceutical company’s stock valued at $3,753,000 after purchasing an additional 700 shares during the period. 75.48% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This piece was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this piece on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be read at https://stocknewstimes.com/2018/02/18/bmo-capital-markets-boosts-intercept-pharmaceuticals-icpt-price-target-to-155-00.html.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply